| Stereochemistry | ACHIRAL |
| Molecular Formula | C3HF7 |
| Molecular Weight | 170.0289 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(C(F)(F)F)C(F)(F)F
InChI
InChIKey=YFMFNYKEUDLDTL-UHFFFAOYSA-N
InChI=1S/C3HF7/c4-1(2(5,6)7)3(8,9)10/h1H
| Molecular Formula | C3HF7 |
| Molecular Weight | 170.0289 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
Patents
Sample Use Guides
The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 h, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)). Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function.
Route of Administration:
Respiratory
